UK medicines regulator approves gene therapy for two blood disorders

MHRA authorises uses of Casgevy as a potential cure for sickle cell disease and beta thalassemiaBritain ’s drugs regulator has approved a groundbreaking treatment for two painful and debilitating lifelong blood disorders, which works by “editing” the gene that causes them.The Medicines and Healthcare products Regulatory Agency (MHRA) has given thegreen light for Casgevy to be used to treatsickle cell disease andbeta thalassemia.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Gene editing Medical research Sickle cell disease NHS Health Society UK news Regulators Science Genetics Pharmaceuticals industry Business Source Type: news